Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to -$2.5 million.

  • Ascendis Pharma A's Gains from Investment Securities fell 137809.6% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.5 million, marking a year-over-year decrease of 3557.91%. This contributed to the annual value of -$6.0 million for FY2024, which is 2415.54% down from last year.
  • As of Q3 2025, Ascendis Pharma A's Gains from Investment Securities stood at -$2.5 million, which was down 137809.6% from -$4.6 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Gains from Investment Securities ranged from a high of $1.6 million in Q4 2022 and a low of -$4.6 million during Q2 2025
  • In the last 5 years, Ascendis Pharma A's Gains from Investment Securities had a median value of -$223790.6 in 2024 and averaged -$898624.8.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first surged by 28257.51% in 2022, then crashed by 137809.6% in 2025.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Gains from Investment Securities stood at $410685.6 in 2021, then surged by 282.58% to $1.6 million in 2022, then plummeted by 314.34% to -$3.4 million in 2023, then surged by 32.19% to -$2.3 million in 2024, then decreased by 11.6% to -$2.5 million in 2025.
  • Its Gains from Investment Securities stands at -$2.5 million for Q3 2025, versus -$4.6 million for Q2 2025 and -$54698.0 for Q1 2025.